63908-28-1

Basic information

• Product Name: Xanthine, 1,8-dimethyl-3-isobutyl-
• Synonyms: Xanthine, 1,8-dimethyl-3-isobutyl-
• CAS NO: 63908-28-1
• Molecular Formula: C11H16 N4 O2
• Molecular Weight: 236.2703
• Mol File: 63908-28-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 462.8°Cat760mmHg
• Flash Point: 233.7°C
• Appearance: /
• Density: 1.242g/cm³
• Vapor Pressure: 9.58E-09mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: Xanthine, 1,8-dimethyl-3-isobutyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Xanthine, 1,8-dimethyl-3-isobutyl-(63908-28-1)
• EPA Substance Registry System: Xanthine, 1,8-dimethyl-3-isobutyl-(63908-28-1)

Safety Data

• Hazardous Substances Data: 63908-28-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H16N4O2/c1-6(2)5-15-9-8(12-7(3)13-9)10(16)14(4)11(15)17/h6H,5H2,1-4H3,(H,12,13)

Upstream product

• 78033-18-8 5,6-diamino-1-isobutyl-3-methyl-1H-pyrimidine-2,4-dione 
• 64-19-7 acetic acid 
• 58481-39-3 6-amino-1-isobutyl-3-methyl-1H-pyrimidine-2,4-dione 
• 38014-54-9 1-isobutyl-3-methyl-urea 
• 54052-67-4 1-isobutyl-3-methyl-5-nitroso-6-amino uracil 

Relevant articles and documents

Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation

A method of treating skin or hair for promoting pigmentation wherein a xanthine component, in an amount effective to promote pigmentation, is incorporated in liposomes or hydrated lipidic lamellar phases.

Long-acting xanthine bronchodilators and antiallergy agents

Prolonged bronchodilation and prolonged inhibition of allergic mediator release in mammals are produced by administering an effective amount of a substituted xanthine compound having the formula: STR1 wherein: R1 = methyl R3 = c4 -c7 alkyl, C4 -C7 cycloalkylalkyl C4 -C7 alkenyl, C4 -C7 alkynyl, or C4 -C7 cycloalkyl R8 = c1 -c2 alkyl These compounds are useful in the treatment of bronchial asthma and other bronchospastic and allergic diseases. The compounds are also novel. The bronchodilator and antiallergy agents may be administered in the form of tablets, capsules, aerosols, solutions, suspensions or suppositories.